Foretinib (GSK-1363089; XL-880; EXEL2880; GSK-089)

Alias: EXEL 2880, XL-880; GSK1363089; GSK 1363089; GSK1363089, EXEL-2880,XL-880; XL880; XL 880; GSK-1363089; GSK089; EXEL2880
Cat No.:V0493 Purity: =99.51%
Foretinib (also known as GSK1363089; XL880; EXEL-2880; GSK089) is a novel, potent, ATP-competitive small-molecule inhibitor of multipletyrosine kinases (e.
Foretinib (GSK-1363089; XL-880; EXEL2880; GSK-089) Chemical Structure CAS No.: 849217-64-7
Product category: VEGFR
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
2mg
5mg
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: =99.51%

Product Description

Foretinib (also known as GSK1363089; XL880; EXEL-2880; GSK089) is a novel, potent, ATP-competitive small-molecule inhibitor of multiple tyrosine kinases (e.g. VEGF) with potential antineoplastic activity. It inhibits vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) receptor. It inhibits the receptors for hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF). Although it was in clinical trials, the development was stopped as of October 2015. With IC50s of 0.4 nM and 0.9 nM, foretinib primarily inhibits Met and KDR. It has minimal effect on Ron, Flt-1/3/4, Kit, PDGFRα/β, and Tie-2, and little effect on FGFR1 and EGFR. Numerous cancers have been found to overexpress the proto-oncogene c-MET.

Biological Activity I Assay Protocols (From Reference)
Targets
Met (IC50 = 0.4 nM); KDR (IC50 = 0.86 nM); Tie-2 (IC50 = 1.1 nM); VEGFR3/FLT4 (IC50 = 2.8 nM); RON (IC50 = 3 nM)
ln Vitro
XL880 inhibits tyrosine kinases of the HGF receptor family, with IC50 values of 3 nM for Ron and 0.4 nM for Met. Moreover, KDR, Flt-1, and Flt-4 are inhibited by XL880, with IC50 values of 0.9 nM, 6.8 nM, and 2.8 nM, respectively. XL880 has an IC50 of 40 nM, 29 nM, and 165 nM, respectively, which inhibits the growth of B16F10, A549, and HT29 cell colonies.[1] According to a recent study, XL880 has different effects on cell growth in the gastric cancer cell lines MKN-45 and KATO-III. In MKN-45 cells, XL880 inhibits the phosphorylation of MET and downstream signaling molecules; in KATO-III cells, it targets GFGR2.[2]
ln Vivo
XL880, administered orally as a single 100 mg/kg dose, significantly inhibits the phosphorylation of B16F10 tumor Met and ligand (e.g., HGFor VEGF)-induced receptor phosphorylation of Met in the liver and Flk-1/KDR in the lung, both of which lasted for a full day. Tumor burden is reduced when XL880 (30–100 mg/kg, once daily, oral gavage) is administered. Treatment with 30 and 100 mg/kg XL880 reduces the lung surface tumor burden by 50% and 58%, respectively. When mice with B16F10 solid tumors are treated with XL880, there is a dose-dependent inhibition of tumor growth of 64% and 87% at 30 and 100 mg/kg, respectively. The administration of XL880 is well tolerated in both studies, and there is no discernible reduction in body weight.[1] XL880 was created to target HGF abnormal signaling through Met and several receptor tyrosine kinases involved in tumor angiogenesis at the same time. In human xenografts, XL880 produced tumor hemorrhage and necrosis in 2 to 4 hours. Maximum tumornecrosis is seen at 96 hours (after five daily doses), leading to total regression.[3]
Enzyme Assay
One of three assay formats—[33P]phosphoryl transfer, luciferase-coupled chemiluminescence, or AlphaScreen tyrosine kinase technology—is used to study kinase inhibition. XLFit is used in nonlinear regression analysis to calculate IC50s. 33P - Transfer of Phosphoryl Assay for Kinase 384-well white, clear-bottomed, high-binding microtiter plates (Greiner, Monroe, NC) are used for reactions. In a 50 μL coating buffer containing 40 μg/mL substrate (poly(Glu, Tyr)), 2 μg/well of protein or peptide substrate is applied to the plates. 3 mM NaN3, 50 mM NaCl, 27.5 mM NaHCO3, and 4:1 can all be found. After incubating at room temperature for the entire night, coated plates are once again washed with 50 μL of assay buffer (RT). In a total volume of 20 μL, test compounds and enzymes are mixed with 33P-γ-ATP (3.3 μCi/nmol). After two hours of RT incubation, aspiration is used to end the reaction mixture. After that, the microtiter plates are cleaned six times using a 0.05% Tween-PBS buffer (PBST). Addition and incorporation of scintillation fluid (50 μL/well) A MicroBeta scintillation counter is used in liquid scintillation spectrometry to measure 33P. Chemiluminescence Assay with Luciferase Coupled Microtiter plates with medium binding (Greiner), measuring 384 wells, are used for conducting reactions. Step one involves mixing the enzyme and compound and letting them sit for 60 minutes. Step two involves adding ATP and peptide substrate (poly(Glu, Tyr) 4:1) in a final volume of 20 μL, then letting them sit for two to four hours at room temperature. After the kinase reaction, a Victor plate reader is used to measure the luminescence signal, and a 20 μL aliquot of Kinase Glo (Promega, Madison, WI) is added. There is a 50% cap on ATP consumption overall. ALPHAScreen Tyrosine Kinase Assay Utilized are acceptor beads coated with PY100 anti-phosphotyrosine antibody and donor beads coated with streptavidin. The substrate is biotinylated poly(Glu,Tyr) 4:1. The addition of donor/acceptor beads and the subsequent formation of a donor-acceptor bead complex are used to measure the substrate phosphorylation. In 384-well white, medium binding microtiter plates (Greiner), kinase and test compounds are mixed and preincubated for 60 minutes. Next, ATP and biotinylated poly(Glu, Tyr) are added in a total volume of 20 μL. The reaction mixtures are allowed to sit at room temperature for one hour. AlphaScreen bead suspension containing 75 mM Hepes, pH 7.4, 300 mM NaCl, 120 mM EDTA, 0.3% BSA, and 0.03% Tween-20 is added to 10 L to quench reactions. Plates are read using an AlphaQuest reader after being incubated for 2–16 hours at room temperature.
Cell Assay
In a 96-well plate containing 10% FBS and EXEL-2880, B16F10, A549, and HT29 cells (1.2 x 103 per well) are combined with soft agar and seeded on top of a base agar layer. The plates are incubated at 37°C for 12 to 14 days in 21% oxygen, 5% CO2, and 74% nitrogen under normoxic conditions. In contrast, the plates are incubated at 37°C under hypoxic conditions in a hypoxia chamber with 1% oxygen, 5% CO2, and 94% nitrogen. After adding 50% Alamar Blue and detecting fluorescence, the number of colonies is assessed for each condition.
Animal Protocol
Mice without tumors or mice carrying B16F10 tumors are used in in vivo target modulation experiments. Oral gavage with 10 mL/kg of foretinib or vehicle (0.9% normal saline) is used. HGF (10 μg/mouse) is given intraperitoneally 10 minutes prior to harvesting in order to assess Met phosphorylation in the liver. Thirty minutes prior to harvest, or half an hour later, mice receive an intravenous injection of VEGF (10 μg/mouse) to assess Flk-1/KDR phosphorylation in the lung. Immunoblot analysis is used to determine receptor phosphorylation.
References

[1]. Cancer Res . 2009 Oct 15;69(20):8009-16.

[2]. Invest New Drugs . 2012 Aug;30(4):1352-60.

[3]. Clin Cancer Res . 2010 Jul 1;16(13):3507-16.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C34H34F2N4O6
Molecular Weight
632.65
Exact Mass
632.24
Elemental Analysis
C, 64.55; H, 5.42; F, 6.01; N, 8.86; O, 15.17
CAS #
849217-64-7
Appearance
Solid powder
SMILES
COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
InChi Key
CXQHYVUVSFXTMY-UHFFFAOYSA-N
InChi Code
InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
Chemical Name
1-N'-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Synonyms
EXEL 2880, XL-880; GSK1363089; GSK 1363089; GSK1363089, EXEL-2880,XL-880; XL880; XL 880; GSK-1363089; GSK089; EXEL2880
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~127 mg/mL (~200.7 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
30% propylene glycol, 5% Tween 80, 65% D5W: 30mg/mL
 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.5807 mL 7.9033 mL 15.8065 mL
5 mM 0.3161 mL 1.5807 mL 3.1613 mL
10 mM 0.1581 mL 0.7903 mL 1.5807 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00920192 Completed Drug: Foretinib Carcinoma, Hepatocellular GlaxoSmithKline August 12, 2009 Phase 1
NCT01147484 Completed Drug: Foretinib Recurrent Breast Cancer NCIC Clinical Trials Group September 2, 2010 Phase 2
NCT01138384 Completed Drug: Foretinib
Drug: Lapatinib
Breast Cancer NCIC Clinical Trials Group October 27, 2010 Phase 1
Phase 2
NCT00742131 Completed Drug: GSK1363089 Solid Tumours GlaxoSmithKline March 17, 2005 Phase 1
NCT00742261 Completed Drug: GSK1363089 Solid Tumours GlaxoSmithKline August 11, 2008 Phase 1
Biological Data
  • Foretinib (GSK1363089)

    EXEL-2880 (XL880, GSK1363089), inhibits migration, invasion, and anchorage-dependent growth of B16F10 cells. Cancer Res. 2009 Oct 15;69(20):8009-16.

  • Foretinib (GSK1363089)

    EXEL-2880 inhibits HMVEC-L tubule formation and migration. Cancer Res. 2009 Oct 15;69(20):8009-16.

  • Foretinib (GSK1363089)

    EXEL-2880 inhibits phosphorylation of Met and Flk-1/KDR and reduces tumor burden in an experimental model of lung metastasis. Cancer Res. 2009 Oct 15;69(20):8009-16.

Contact Us